Our Story
Aurobindo Through the Years
Creation of a Leading Vertically Integrated Platform
2020
2019
Auro Packaging – Packaging Division.
2018
Acrotech Biopharma – Brand Division. Acquired seven marketed oncology products from Spectrum Pharmaceuticals.
2017
Opened 567,000 sq. ft. fully automated state-of-art distribution center in East Windsor, NJ
Opened a new, 40,000 sq. ft. specialty pharma R&D facility in Durham, NC
APL acquired 4 cell culture-derived biosimilar products from Swiss TL Biopharmaceutical. Three out of the four biosimilars are monoclonal antibodies in oncology.
APL acquires Portugal’s Generis Farmaceutica SA
2016
Aurobindo Pharma USA, Inc. moves Corporate Headquarters to East Windsor, NJ, USA
2015
Investment into Tergene to fund the development of a pneumonia vaccine
2014
Aurobindo Pharma USA, Inc. acquires Natrol Inc. in California, USA
Aurohealth LLC begins doing business in Lawrenceville, NJ, USA
Focus on differentiated technology platforms eg. depot injections
APL acquires commercial operations in Western Europe from Actavis making it one of the leading Indian pharmaceutical companies in Europe.
2013
Commenced marketing specialty injectables to fund the development in USA through AuroMedics
Building capabilities in Penem, Oncology & Biocatalysis
2012
First approval of Controlled Substance formulations in USA
Set up AuroPeptide to foray into peptide business
Aurohealth LLC, our OTC division becomes an entity
2011
AuroMedics Pharma LLC begins selling and distributing Injectables in the USA
2010
Commenced operations of SEZ Unit VII and Aurolife, USA facilities and divested Chinese antibiotics products facility
2008
Aurolife Pharma LLC begins manufacturing solid oral dose.
2007
Acquired formulations facility in USA
Investment in building manufacturing, marketing & IPR capabilities
2006
Acquired building from Sandoz to begin Aurolife Manufacturing in Dayton, NJ, USA
2004
Aurobindo Pharma USA, Inc. becomes incorporated in USA
1992-2002
Commencement of export of APIs
Initial Public Offering (1995)
Began production of formulations